We revamp the HEOR strategy by redesigning the model, analysing outcomes, and aligning the global and UK HEOR strategy to guide successful market access and pricing decisions.
We are technically astute, with experts who bring deep healthcare strategy and clinical knowledge to every project.
Data deep dive
Our client lacks mature OS data demonstrating long-term real-world effectiveness of their product and requires a re-boot.
Model technical and strategic review
We conduct a thorough review of an existing global partitioned survival model developed by an external agency, identifying two key issues:
The existing model fails to capture the product’s broader indication and observed PFS benefits.
The survival extrapolations do not follow NICE DSU guidelines.
Practical Agility
We are practically agile, operating with a lean structure that allows seamless teamwork and swift resource deployment, ensuring efficient project completion without unnecessary bureaucracy.
Model design
We develop a decision analytic model based on a structure previously accepted by NICE.
Outcomes analysis
We use the competitor’s pivotal trial publication to establish a relationship between mean PFS benefit and mean OS benefit.
Global HEOR strategy
We make strategic recommendations for global and UK-specific HEOR and NICE tactics, adopting the NICE HEOR strategy as the global standard, which is then implemented across European launches.
Internal training
We deliver training sessions to support access and pricing decision-making.
FIECON exceeds my expectations by genuinely trying to achieve the best outcomes for our company. Their flexibility to adapt to unexpected changes and apply technical rigour, while respecting the commercial focus of the company is unparalleled. We see FIECON as part of our extended team.”
Senior Market Access Manager, Mid-sized Pharma
It was brilliantly smart and very well explained. It seems obvious now but that is what genius is, making complex things appear simple.”
Associate Director, Mid-sized Pharma
FIECON are my go to trusted partner. The team deliver high-quality work to timeline, every time. But more than this, FIECON has worked as part of our team, working towards achieving the best possible outcome by providing high level strategic input and challenge during our discussions.”
Market Access Director, Small Biotech
FIECON’s highly skilled expert team helped us to successfully tackle a number of tough pricing and access challenges. Apart from their flawless technical expertise, we have a reliable thought partner to pressure test new ideas and strategies that have a broader relevance than purely health economic aspects.”
Disease Area Director, Big Pharma
The pricing and market access research was a high quality work project, which included detailed information to define the overall and country strategy while the gap analysis was instrumental in the next steps preparation. ”
Executive Director, Biotech
FIECON’s strategic approach to problem solving is a breath of fresh air. We highly value their HTA knowledge and expertise, and they consistently deliver the best solution for us.”
Value Demonstration & Access Lead, Big Pharma
It is a pleasure to work with FIECON. The team are passionate about what they do and it really shows in their high-quality, creative solutions. Working with FIECON gives your projects the highest chance of success.”
Senior Vice President, Small Biotech
FIECON’s team is highly experienced, commercially focused, responsive and flexible. A particular strength I highlight is that FIECON’s team becomes a true partner with all company functions that they interact with. ”
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage and assist in our marketing efforts. More info
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage and assist in our marketing efforts.
